SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cocrystal Pharma, Inc. f/k/a BioZone - COCP

Tuesday, October 2, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Oct. 2, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cocrystal Pharma,

Inc. ("Cocrystal" or the "Company") (NASDAQ: COCP) (f/k/a BioZone Pharmaceuticals, Inc. ("BioZone"). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The

investigation concerns whether Cocrystal and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here to join a class action]

On September 7, 2018, the U.S. Securities and Exchange Commission ("SEC") issued a press release entitled "SEC Charges Microcap Fraudsters for Roles in Lucrative Market Manipulation Schemes".  The press release stated, in part, that the SEC had "charged a group of 10 individuals and 10 associated entities for their participation in long-running fraudulent schemes that generated over $27 million from unlawful stock sales and caused significant harm to retail investors who were left holding virtually worthless stock."  The press release named three controlling shareholders of Cocrystal's corporate predecessor BioZone—Barry C. Honig, Michael Brauser, and Phillip Frost—as defendants. 

Following this announcement, Cocrystal's stock price fell $0.58 per share, or over 15.5%, over the next two trading sessions to close at $3.16 on September 11, 2018.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:Robert S. WilloughbyPomerantz LLPrswilloughby@pomlaw.com888-476-6529 ext. 9980

 

Cision View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-cocrystal-pharma-inc-fka-biozone---cocp-300723072.html

SOURCE Pomerantz LLP



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store